Immix Biopharma, Inc.

NasdaqCM:IMMX Stock Report

Market Cap: US$64.6m

Immix Biopharma Future Growth

Future criteria checks 2/6

Immix Biopharma is forecast to grow earnings and revenue by 3.4% and 171.4% per annum respectively while EPS is expected to grow by 22.8% per annum.

Key information

-11.4%

Earnings growth rate

8.1%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate171.4%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Jan 2025

Recent future growth updates

No updates

Recent updates

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?

Nov 11
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Aug 12
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Nov 28
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

Jul 12
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Mar 29
We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Sep 13
Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

May 21
We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

NasdaqCM:IMMX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20256-26N/AN/A1
12/31/20242-24N/AN/A1
9/30/2024N/A-22-16-16N/A
6/30/2024N/A-19-15-15N/A
3/31/2024N/A-18-13-13N/A
12/31/2023N/A-15-11-11N/A
9/30/2023N/A-14-13-13N/A
6/30/2023N/A-11-11-11N/A
3/31/2023N/A-9-8-8N/A
12/31/2022N/A-8-7-7N/A
9/30/2022N/A-27-5-5N/A
6/30/2022N/A-26-3-3N/A
3/31/2022N/A-25-3-3N/A
12/31/2021N/A-24-2-2N/A
9/30/2021N/A-200N/A
6/30/2021N/A-200N/A
3/31/2021N/A-200N/A
12/31/2020N/A-100N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMMX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMMX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMMX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMMX's revenue (171.4% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: IMMX's revenue (171.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IMMX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 22:32
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immix Biopharma, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research
Robert BurnsH.C. Wainwright & Co.
Jonathan AschoffRoth MKM